Welcome to our dedicated page for Aura Biosciences news (Ticker: AURA), a resource for investors and traders seeking the latest updates and insights on Aura Biosciences stock.
Aura Biosciences, Inc. (AURA) is a clinical-stage biotechnology company pioneering precision therapies that target solid tumors while preserving critical organ function. This page serves as the definitive source for investors and medical professionals tracking the company's progress in ocular oncology and bladder cancer treatments.
Access real-time updates on clinical trial developments, regulatory milestones, and strategic partnerships. Our curated news collection includes press releases covering drug candidate advancements (including lead program bel-sar), financial disclosures, and scientific presentations—all essential for evaluating AURA's position in targeted cancer therapeutics.
Key content categories include clinical trial phase updates, FDA designation announcements, collaborative research initiatives, and financial performance reports. The company's innovative molecular surgery approach—combining direct tumor targeting with immune activation—is reflected across all coverage.
Bookmark this page for streamlined monitoring of AURA's progress in vision-preserving ocular melanoma treatments and organ-sparing bladder cancer therapies. Check regularly for authoritative updates on this clinical-stage innovator's journey through the drug development pipeline.
Aura Biosciences Inc. (AURA) announced the publication of preclinical data for AU-011, its first Virus-Like Drug Conjugate (VDC) candidate, at the 2022 ASCO Annual Meeting. The combination of AU-011 with immune checkpoint inhibitors demonstrated effectiveness against primary tumors and metastases in preclinical models, suggesting potential for treating life-threatening cancers such as choroidal melanoma and non-muscle invasive bladder cancer. The research highlights collaboration with Leiden University Medical Center, enhancing the clinical prospects of AU-011.
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology firm, has announced participation in two upcoming investor conferences. The first is Cowen's Virtual 3rd Annual Oncology Innovation Summit on June 2, 2022, featuring a fireside chat at 9:00 a.m. ET. The second is the Jefferies Global Healthcare Conference on June 8, 2022, with a presentation at 1:30 p.m. ET. Live webcasts for these events will be available on the company's website, with replays archived for 90 days. Aura is developing virus-like drug conjugates for various oncology indications, currently focusing on AU-011 for ocular cancers.
Aura Biosciences Inc. (NASDAQ: AURA) announced significant clinical milestones for AU-011 in oncology, including the initiation of pivotal trials in choroidal melanoma and phase 1 trials for non-muscle invasive bladder cancer. The company reported Q1 2022 financials, showing a net loss of $12.8 million, up from $5.9 million in Q1 2021. Operating expenses rose due to increased R&D and administrative costs. As of March 31, 2022, Aura had $133.3 million in cash, sufficient to fund operations into 2024. The company maintains a focus on developing VDC therapies for various cancer indications.
Aura Biosciences (NASDAQ: AURA) presented new preclinical data for its VDC product candidate, AU-011, at the ARVO Annual Meeting in Denver. The data indicates AU-011's targeted cytotoxicity against tumor cells commonly metastasizing to the choroid, including breast, renal, and colon cancers. CEO Elisabet de los Pinos emphasized the potential of AU-011 as a treatment for ocular cancers. The company plans to submit an IND for choroidal metastasis in the latter half of this year, further advancing its ocular oncology initiatives.
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology firm, announces that CEO Elisabet de los Pinos will present at the 2022 Bank of America Healthcare Conference in Las Vegas on May 10, 2022, at 4:55 p.m. PT. The presentation will be available via a live webcast on Aura's website, with a replay accessible for 90 days thereafter.
Aura specializes in virus-like drug conjugate therapies for oncology, with its lead candidate, AU-011, targeting ocular cancers, specifically choroidal melanoma. The company aims to broaden the use of AU-011 in multiple cancers, including bladder cancer.
Aura Biosciences reported its financial results for the fourth quarter and year ending December 31, 2021, highlighting advancements in its AU-011 program. The company is set to initiate pivotal trials for early-stage choroidal melanoma and a Phase 1 trial for non-muscle invasive bladder cancer in the second half of 2022. Aura received Orphan Drug Designation from the European Commission for AU-011, enhancing its market position. The cash position of $149.1 million is expected to fund operations into 2024, despite increased R&D expenses resulting in a net loss of $35.3 million for the year.
Aura Biosciences Inc. (NASDAQ: AURA) has received Orphan Drug Designation from the European Commission for its first virus-like drug conjugate (VDC) candidate, AU-011, aimed at treating uveal melanoma, including choroidal melanoma. Choroidal melanoma represents 90% of uveal melanomas and currently lacks approved therapies for early stages. This designation highlights the urgent need for treatment options. AU-011 is now in Phase 2 clinical trials and is expected to expand into choroidal metastasis. The company is aligned with U.S. and European agencies for its pivotal programs.
Aura Biosciences Inc. (NASDAQ: AURA) will host a virtual Investor Day on March 22, 2022, from 11:00 a.m. to 12:30 p.m. ET. The event will feature presentations by notable ocular oncology experts, Dr. Carol Shields and Dr. Hans Grossniklaus, focusing on choroidal melanoma and the novel therapy AU-011. The company plans to finalize the treatment regimen for AU-011 and initiate a pivotal program in the latter half of 2022. The event can be accessed via phone or through a live webcast on Aura's investor website.
Aura Biosciences Inc. (NASDAQ: AURA) presented preclinical data for its first Virus-Like Drug Conjugate (VDC) candidate, AU-011, at the 2022 American Association for Cancer Research Annual Meeting. Targeting aggressive cancers like primary choroidal melanoma and non-muscle invasive bladder cancer, results indicate AU-011's potential effectiveness across multiple solid tumor types. The findings enhance understanding of tumor cell biology and signal opportunities for expanding clinical trials. The company is focused on developing AU-011 for ocular and potentially broader oncological applications.
Aura Biosciences Inc. (NASDAQ: AURA), a biotechnology firm focused on innovative virus-like drug conjugate (VDC) therapies for cancer, announced CEO Elisabet de los Pinos will join a panel discussion on “Auditory and Ophthalmology” at the 42nd Annual Cowen Virtual Health Care conference on March 7, 2022, at 2:10 p.m. ET. A live webcast will be available on the company’s website, with a replay archived for 90 days. Aura’s lead candidate, AU-011, targets ocular cancers and is undergoing a Phase 2 clinical trial for choroidal melanoma, a severe eye cancer.
FAQ
What is the current stock price of Aura Biosciences (AURA)?
What is the market cap of Aura Biosciences (AURA)?
